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Background: Adjudicated cause-specific mortality has been used in major trials of chronic obstructive 
pulmonary disease (COPD). However, there is less experience with adjudicated major adverse 
cardiovascular events (MACE) as a key efficacy outcome in COPD trials. The Study to Understand 
Mortality and Morbidity in COPD (SUMMIT) study trial required a Clinical Endpoint Committee (CEC) to 
adjudicate the outcomes of modified MACE and cause-specific mortality. 
Methods and results: A six-member CEC reviewed adverse event (AE) and serious adverse event AE 
(SAE) reports included in a list of 204 Medical Dictionary for Regulatory Activities MedDRA terms. 
Adverse events AEs were triaged by one CEC member then reviewed by three reviewers (round 1). If 
these three disagreed on the adjudication, the event was discussed by the full committee to reach a 
consensus (round 2). Among 16,485 participants, 48,105 adverse events AEs were reported, among 
which 3314 were reviewed by the CEC. After triage, 1827 were adjudicated in round 1; 338 required 
committee consensus in round 2, yielding 450 myocardial infarctions, strokes, unstable anginas or 
transient ischaemic attacks. Only 20/1627 (1%) non-serious adverse events AEs were adjudicated as 
cardiovascular events. Only 45/204 Medical Dictionary for Regulatory Activities MedDRA terms reviewed 
yielded cardiovascular events. 430 deaths were adjudicated in round 1 and 631 in round 2, yielding 459 
cardiovascular deaths. Adjudication of chest pain and sudden death often required additional 
information from site investigators. Site assessment of cardiovascular death was moderately specific 
(501/602=83%) but not sensitive (256/459=56%). 
Conclusions: A CEC is useful for adjudication of MACE in COPD trials but requires considerable resources 
and effort by investigators. This process can be streamlined by reviewing only SAEs serious adverse 
events and filtering by selected Medical Dictionary for Regulatory Activities MedDRA terms. 
Clinical trial registration: NCT01313676 https://clinicaltrials.gov/ct2/show/NCT01313676 
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Cardiovascular co-morbidities are common in chronic obstructive pulmonary disease (COPD) and often 
lead to major adverse cardiovascular events (MACE). Cause-specific mortality has become a routine 
adjudicated outcome in large COPD clinical trials, and the methods and experience of the adjudication 
process have been reported previously.1−3 Although MACE is a common outcome measure in 
cardiovascular clinical trials, it has not been widely used as an adjudicated efficacy or safety outcome for 
COPD trials. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) was a large COPD 
clinical trial that tested the secondary hypothesis that fluticasone furoate/vilanterol (FF/VI) combination 
treatment would reduce risk of MACE in mild-moderate COPD patients with increased cardiovascular 
risk factors.4,5 To this end, SUMMIT required the development of a process and procedures for collecting 
and adjudicating cause-specific mortality and MACE. For SUMMIT, the definition of MACE included 
transient ischaemic attacks (TIA) and unstable angina (UA) as well as myocardial infarction (MI), stroke, 
and cardiovascular death. To accomplish this task, a Clinical Endpoint Committee (CEC) was established 
and principles of operation, based on published guidelines for cardiovascular trials, were adapted for 
review of SUMMIT events. From the extensive experience accrued from this study, we learned lessons 
that may be employed in future COPD trials in which MACE is an efficacy or a safety outcome. The 
purpose of this report is to provide post hoc details of the process, the efficiency of MACE 
ascertainment methods, and the extent of agreement between adjudicated events and site-investigator 





SUMMIT study design 
 
The SUMMIT study design and primary outcomes have been previously reported.4,5 Briefly, the trial was 
a randomised, double blind, parallel group event-driven trial comparing fluticasone furoate/vilanterol 
FF/VI and placebo, inhaled once daily. Enrolled participants had moderate COPD (post-bronchodilator 
forced expiratory volume in 1 second [FEV1] 50–70% predicted) and increased risk for cardiovascular 
disease. Each participant was followed from enrolment to at least the common end date, at which there 
were projected to be 1000 deaths. The primary outcome was all-cause mortality up to the common end 
date, however all deaths reported before the database was locked were adjudicated. The secondary 
outcomes were rate of decline in forced expiratory volume in 1 second FEV1 and a cardiovascular 
composite endpoint (MACE) comprising on-treatment MImyocardial infarction, stroke, transient 
ischaemic attackTIA, unstable anginaUA and cardiovascular death. All patients provided written 
informed consent. The study was approved by local ethics committees and was conducted in accordance 
with the Declaration of Helsinki and Good Clinical Practice guidelines. 
 
Acquisition of medical information 
 
When a participant died or reported any adverse event (AE) to the local site, the adjudication process 
was initiated. For each death, the site was asked to provide as much information as possible to facilitate 
the adjudication of the primary cause of death including death certificate, hospital correspondence, 
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results of clinical investigations, procedure reports, witness interviews and autopsy results where 
available. When a site reported an adverse event AE into the electronic case report form, the verbatim 
term was coded by a central automatic coding procedure to a MedDRA (Medical Dictionary for 
Regulatory Activities (, version 18) preferred term. If this Medical Dictionary for Regulatory Activities 
MedDRA term matchedmapped to a list of preferred terms of pre-defined events, then the adverse 
event AE was sent for adjudication for a CVcardiovascular event. from MedDRA (Medical Dictionary for 
Regulatory Activities, version 18). These pre-defined events were chosen by a physician reviewing all 
Medical Dictionary for Regulatory Activities MedDRA preferred terms prior to the adjudication process 
starting. For these events, sites were also requested to provide all available medical records to support 
the determination of causation of death and hence whether this was a component of MACE. 
 
Operation of the Clinical Endpoint Committee 
 
The CEC comprised six physicians, two each from the following specialties: Pulmonology, Cardiology and 
Neurology. The CEC members were not site investigators in the study. The committee members were 
selected by the sponsor and approved by the SUMMIT steering committee. The CEC operated under a 
charter written by the sponsor and created a principles of operation document that was written by the 
CEC members and was updated throughout the study to codify guidelines for adjudicating the 




The Virtual virtual Clinical clinical Adjudication adjudication System system (VCAS) was a web-based 
application for central management of information retrieval and adjudication activities developed for 




SUMMIT (PAREXEL, Waltham, MA, USA). When an event occurred for a subject, relevant clinical 
documents were collected in the virtual clinical adjudication system VCAS to create an electronic 
dossier. Reviewers recorded their assessments in the virtual clinical adjudication system VCAS and if 
discordance was found, the case was automatically distributed for consensus review. 
 
Adjudication of cause-specific death and MACE 
 
The process for adjudicating the primary cause of death and assessing whether or not it was related to 
COPD was similar to that followed in recent large respiratory trials.1–3 In brief, the adjudicated cause of 
death was classified based on the underlying cause of death defined as the presenting illness that 
preceded the terminal events, not the terminal events just preceding death. Adjudication of MACE 
events generally followed the Food and Drug Administration (FDA) guidance for cardiovascular 
outcomes.6  
 
Sudden death is a term generally denoting a presumed arrhythmic death when the death is witnessed 
(i.e. the person is found dead seen alive within 1 hour of being  seen alivefound dead), and another 
cause could not be identified. In SUMMIT it was included as a subcategory of cardiovascular deaths. If a 
death was unwitnessed and occurred within 1–24 hours of the patient last being seen alive without 
evidence of clinical deterioration and no other cause of death was ascertained, it was also categorised as 
a sudden death as well as a cardiovascular death. If the interval between death and last being observed 
alive was greater than 24 hours, and there was no other cause of death, the death was classified as 
unknown. This information was systematically obtained by the sites for deaths occurring outside of 
medical facilities by a standardised interview with a family member or witness. 
 




Myocardial Infarctions infarctions were adjudicated using published criteria using cardiac enzymes, 
electrocardiograph (ECG) changes, imaging or pathologic evidence.7 Stroke was diagnosed based on 
compatible neurologic symptoms supported by brain imaging or onset of a typical acute neurologic 
deficit. Unstable angina was diagnosed based on the need for unscheduled medical care associated with 
compatible electrocardiograph ECG or imaging evidence of coronary stenosis or need for a 
revascularisation procedure. Transient ischaemic attack was defined as a witnessed, transient 
compatible neurologic deficit lasting less than 24 hours in the absence of imaging evidence of a stroke. 
Amaurosis fugax, although representing ocular rather than brain ischaemia, was also classified as a 




Potential MACE events were adjudicated in three stages: a triage round by one committee member, 
round 1 adjudication by three committee members, and round 2 by the entire committee of six. All non-
serious AEs adverse events that matched the selected list of Medical Dictionary for Regulatory Activities 
MedDRA preferred terms was assigned to a single member of the committee in the triage round. The 
committee member reviewed the available documentation and determined whether the event 
warranted further adjudication. If yes, the event was escalated to round 1. All deaths and serious 
adverse eventsAEs (SAEs) were automatically assigned to round 1. In round 1, each event and all the 
accompanying information was sent to three CEC members, one of each specialty. If all three members 
adjudicated the event in an identical fashion, the event was considered adjudicated. If there was 
disagreement on any field of the adjudication form, then the event was escalated to round 2, which was 
a face to face meeting or internet conference with all six members discussing the event and associated 






Overall, among the 16,485 participants, SUMMIT reported 48,105 on-treatment adverse events AEs 
(includes fatal and non-fatal), of which 3,314 (7%) matched the list of pre-defined MedDRA preferred 
terms. These were subsequently reviewed by the CEC. Of these, 1,687 were SAEs serious adverse events 
and 1,627 were non-serious adverse eventsAEs. 450 AEs adverse events were adjudicated as 
MImyocardial infarctions, strokes, TIA transient ischaemic attacks or UAunstable angina, of which 387 
were non-fatal. Only 20 (1%) of the 1,627 non-serious adverse events AEs were finally adjudicated as 
cardiovascular events, whereas 430 (25%) of the 1,687 serious adverse events SAEs were finally 
adjudicated as cardiovascular events. Of these 450 adjudicated events 43% were myocardial 
infarctionsMI, 30% were strokes, 19% were unstable anginaUA, and 8% were transient ischaemic attacks 
TIA (Figure 1a). Out of 70 transient ischaemic attacks TIA preferred terms, 30 (43%) were adjudicated as 
cardiovascular events. 
 
Of the 1,061 deaths in the study, 1,037 (98%) were in the intent-to-treat population and occurred on or 
before the common end date so were included in the SUMMIT primary analysis.5 Of the 1,061 total 
deaths, 4% were an myocardial infarctionsMI, 4% were strokes, 30% were sudden deaths, 1% were 
procedural deaths, and 5% were of other cardiovascular causes (e.g. aortic aneurysm), giving a total of 
459 (43%) classified as cardiovascular death. The other causes of death included cancer (23%), 




Because the secondary outcome measure of interest was time to first event, participants who had two 
events had only the first event included in the primary analysis, consisting of 688 first on-treatment 
cardiovascular events (359 non-fatal and 329 fatal, Figure 1cTable 2). 
 
To capture all events that could be potentially a MACE, the committee reviewed events described by 
204 Medical Dictionary for Regulatory Activities MedDRA terms that occurred in the study. However, 
only 45 of the 204 Medical Dictionary for Regulatory Activities MedDRA terms that were used to filter 
events for adjudication finally yielded an adjudicated MACE. (Online Supplementary Appendix B, Figure 
S1 and Table S1). Some terms were very specific. For example, 82/97 (85%) events with the preferred 
term ‘acute myocardial infarction’ and 73/115 (63%) with the preferred term ‘myocardial infarction’ 
were adjudicated as MACE. In contrast, only 8/352 (2%) of events with the term ‘chest pain’ were finally 
adjudicated as a MACE. 
 




In general, the CEC had good agreement and was able to adjudicate 317 (70%) of the non-fatal MACE 
with all three adjudicators agreeing on all elements of the adjudication in round 1. Of the 450 non-fatal 
MACE, 133 (30%) required promotion to the full six-member committee where a consensus was reached 
in all cases. 
 
Overall, there was good agreement between individual adjudicators and the final committee consensus 
with respect to the primary class of death (e.g. cardiovascular, pulmonary, cancer). Among the six 
adjudicators a total of 3,878 records were reviewed initially and 3,286 (85%) were ultimately consistent 
with the committee’s final adjudication. The percent agreement of individual adjudicators agreement 
with the final cause of death category ranged from 75% to 91% (online Online Supplementary Appendix 
B, Table S2). 
  
Agreement with site investigators 
 
As noted in prior COPD trials, the agreement between the CEC and the site investigator for underlying 
cause of death varied by category. In general, there was good agreement for cancer related deaths, the 
CEC agreeing with the investigator in 192/194 (99%) of cases whereas the committee agreed with the 
site investigator in only 256/357 (72%) of cases initially classified by the site investigator as a 
cardiovascular death (Table 1).  
Overall, the site investigator classifications had a specificity of 83% (501/602) and a sensitivity of 56% 
(256/459) with regards to cardiovascular deaths. 
 
  






In this manuscript, we present the operations and outcomes of the SUMMIT CEC to adjudicate MACE in 
patients with mild-moderate COPD and at risk for cardiac disease. Although cause-specific mortality has 
been well-established as an outcome measure for large-scale clinical trials in COPD, SUMMIT was the 
first major COPD clinical trial to incorporate MACE as a key efficacy outcome measure, rather than . In 
general, when MACE is reported in COPD trials, it is used as a safety measureevaluating this in the 
context of safety.8 Because cardiovascular events are common in patients with COPD, and because these 
events are often preceded by COPD exacerbations, it seems likely that future treatment trials targeting 
COPD exacerbations will place greater scrutiny on these as key clinical outcomes.;89 Procedures for 
adjudication of MACE and cardiac death have been widely used in heart disease trials, but that 
experience has been less frequently reported for COPD outcomes and has been evaluated in the context 
of safety rather than efficacy.9 We thus we report here our experience with a large trial of mild-
moderate COPD patients at risk for cardiac disease in order to report lessons learned and provide 
recommendations for future studies. 
 
In organising the CEC for a trial the size of SUMMIT, it was necessary to construct a large infrastructure 
to collect, organise, translate, and distribute the pertinent case report forms and clinical source material 
and documents that were reviewed by the committee, and to triage reports using a staged approach. In 
SUMMIT, this was facilitated by the development of a data platform (VCAS) that allowed CEC members 
to review collected information and to complete adjudication forms electronically. Because of the scope 
of the review, it was not possible to have all six committee members review all cases, so we used a 
staged approach that permitted triage of reports. First, all AEs were filtered by specific terms that 
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suggested possible MACE. Second, non-serious AEs of interest were triaged by a committee member to 
exclude unlikely events. Third, SAEs and non-serious AEs that were not excluded by triage were 
reviewed by three committee members. If the three committee members did not agree entirely, the 
event was promoted to the full review by the six-member committee for development of a consensus. 
Ultimately, the committee was able to reach a consensus in every case, although sometimes this 
required tabling an event for review at a second meeting. The initial in-person meetings, and discussion 
of example cases to establish rules for evaluation of cases, along with written principles of operation to 
codify these criteria was helpful for establishing the norms for the committee. It was also helpful to have 
specialised expertise in neurology, cardiology, pulmonary and critical care for evaluation of difficult 
cases. 
 
We learned from this experience that the effort involved in reviewing non-serious reports of events 
yielded few MACE events, even after filtering for cardiovascular and related terms, with only 1.2% of 
these reviews ultimately yielding an outcome event, accounting for only 4% of the final total MACE. 
Therefore, in circumstances where resources are particularly constrained, it may be justified to review 
only SAEsserious adverse events, i.e. those that lead to hospitalisation, death or are considered life-
threatening. 
 
Even among SAEs serious adverse events where medical records were available, some diagnostic terms 
were challenging for the committee. For example, the diagnosis of UA unstable angina presented a 
challenge to the committee requiring a second round of review in 39% of cases. We found that the 
hospital diagnosis of unstable angina UA was often used for patients with stable angina who were 
admitted to the hospital for elective procedures such as coronary arteriography. In line with the FDA 
Food and Drug Administration draft guidance, the committee required three elements to adjudicate 
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unstable anginaUA: 1) a pattern of symptoms compatible with unstable anginaUA, 2) an urgent, 
unscheduled admission to a healthcare facility, and 3) anatomic evidence of coronary artery disease or 
performance of a coronary intervention. With this definition, of 88 events with an SAE severe adverse 
event coded as unstable anginaUA, 6 (7%) were adjudicated as a myocardial infarctionn MI, and only 32 
(36%) were adjudicated as unstable anginaUA. Thus, a revascularisation procedure per se did not 
constitute a MACE event unless it was in the context of an acute worsening of symptoms. 
TIAs Transient ischemic attacks were also challenging to adjudicate because of the requirement for 
definite evidence of neurologic symptoms and absence of findings of stroke. Among 45 severe adverse 
events SAEs that were reported as transient ischemic attacksTIAs, only 24 (53%) were finally adjudicated 
as transient ischemic attacksTIA. We also note that congestive heart failure events were reported only 
187 times and that only 2.7% were adjudicated as MACE. We speculate that this low yield may be due to 
the difficulty in distinguishing acute left ventricular failure from an exacerbation of COPD with cor 
pulmonale, emphasizing the need for consistent adjudication of both cardiovascular events and COPD 
exacerbations. 
 
In contrast, severe adverse events SAEs with the diagnosis of ‘acute myocardial infarction’ were more 
accurate – adjudicated as an myocardial infarctionMI  81% of the time (78/96 events). If the severe 
adverse event SAE Medical Dictionary for Regulatory Activities MedDRA term was simply ‘myocardial 
infarction’, then only 73/114 (64%) events adjudicated as a myocardial infarctionn MI. Based on this 
experience, caution is warranted in the use of severe adverse events SAEs as reliable surrogates for 
MACE events in clinical trials. 
 
The committee also classified all myocardial infarctions MIs as either type 1 (coronary artery 
obstruction) or type 2 (oxygen-demand ischaemia). COPD exacerbations increase the risk of an 




myocardial infarction MI about 2 to 4-fold after a COPD exacerbation.8,10 It has been hypothesised that 
these events are brought on by increased myocardial oxygen demands from the combination of 
hypoxemia and beta-agonist use raising the hypothesis that there would be an excess of type 2 
myocardial infarctions MIs in a COPD population. This was not found to be the case. In observational 
series of acute myocardial infarctionMI, only 10–14% are classified as type 2 events.11,12 This is 
comparable to the experience in SUMMIT where, of 173 myocardial infarctionsMIs, 20 (11.5%) were 
adjudicated as type 2 events. Thus, it seems plausible that other factors such as increased platelet 
aggregation are related to the risk of myocardial infarction MI and stroke immediately following a COPD 
exacerbation.13 
 
Early in the operation of the committee, we found that the AE adverse event of ‘chest pain’ or ‘chest 
discomfort’ was a frequent occurrence and that medical records were sparse. To better evaluate these 
reports, we provided site investigators with a specific questionnaire to assess whether this was likely 
due to ischaemic heart disease. Among 389 adverse events AEs that were not considered serious, only 3 
(0.7%) were adjudicated as a MACE event (2 myocardial infarction MI and 1 unstable anginaUA). The 
yield was higher from the term ‘chest pain’ when it was associated with an SAE serious adverse event. 
Among 53 such serious adverse eventsSAEs, 6 (11%) were adjudicated as MACE (4 myocardial infarction 
MI and 2 unstable anginaUA). 
 
Assessment of sudden or unwitnessed death is a particularly difficult problem in COPD populations since 
some of these deaths may be the result of respiratory events as well as cardiovascular death.5 In line 
with previous adjudication committees,1–3,14  we used arbitrary definitions of sudden death in the 
absence of a presenting acute illness and relied upon interviews with family or caretakers to help in this 
process. Among 320 deaths finally adjudicated as sudden death, only 189 (59%) were reported as such 
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by site investigators. When the death was unwitnessed, but the participant was found dead within 24 
hours of being in usual health (often a nocturnal event), the committee had to review the case as a 
whole in round 2 in 111/156 cases (71%) which was the most frequent death event requiring full 
committee consensus with only 45/156 (29%) reaching agreement at round 1. When the death was 
witnessed within 1 hour, there was greater consensus with 82/164 (50%) of these events confirmed on 
round 1, and 82/164 (50%) requiring discussion of the full committee. 
 
In summary, we report here the procedures and experience of the SUMMIT CEC with respect to cause-
specific mortality and MACE. A major lesson that we have derived from this experience is that an 
extensive infrastructure and defined procedures are necessary to accomplish these adjudications. We 
also observed that only 22% of preferred Medical Dictionary for Regulatory Activities MedDRA terms 
yielded adjudicated events and that AEs adverse events that were not considered to be serious events 
rarely yielded MACE events. Thus, in future studies, considerable efficiency could be achieved by tighter 
filtering of terms reviewed by the committee or even eliminating review of events not deemed serious 
by the site investigator. Although all-cause mortality is a more robust outcome measure in clinical trials 
than cause-specific mortality, assessment of cardiovascular death is an important component of MACE 
where cardiovascular safety or efficacy outcomes are critical. In this case, we believe that it is essential 
to rely on an adjudication committee for this outcome rather than site investigator reports. Considering 
the CEC adjudication of cardiovascular deaths as the reference standard, site investigator classification 
was not particularly reliable with a specificity of 83% (501/602) and a sensitivity of only 56% (256/459). 









Anonymised individual participant data and study documents can be requested for further research 
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Figure. 1.  
Adjudication flow chart for (a) adverse events and (b) deaths (c) SUMMIT secondary endpoint.  
CED, common end date for participants; CV, cardiovascular; MI, myocardial infarction; TIA, transient 
ischaemic attacks; UA, unstable angina. 
The 450 events in (a) refer to the four main components of the predefined major adverse 
cardiovascular events (MACE): fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, 
unstable angina (all non-fatal) and transient ischaemic attack (all non-fatal). 
*Sites entered adverse events using the usual process of describing the event with a “verbatim 
term”. The verbatim term was coded by a central automatic coding procedure to a Medical 
Dictionary for Regulatory Activities preferred term. If this Medical Dictionary for Regulatory Activities 
preferred term matched a pre-specified list (see Online Supplementary Appendix B, Figure S1 and 
Table S1) then this triggered the adjudication process. 
Round 1 = Independent review by three committee members; Round 2 = Consensus discussion 
among all committee members. 
*SUMMIT secondary endpoint was time to first on-treatment CV composite event (which includes 
on-treatment CV death). Patients may have experienced multiple CV events, but only the first was 
used in the analysis; †Total = fatal + non-fatal 
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Agreement (diagonal) of cause of death between Primary Investigator and Clinical Endpoint 




CAUSE OF DEATH 
Clinical Endpoint 
Committee 
ADJUDICATED CAUSE OF 
DEATH 
Cardiovascular Pulmonary Cancer Other Unknown Total (%) 
Cardiovascular 256 (72%) 24 0 74 105 459 (43%) 
Pulmonary 21 73 (62%) 0 33 11 138 (13%) 
Cancer 9 8 192 (99%) 23 11 243 (23%) 
Other 19 3 0 61 (28%) 6 89 (8%) 
Unknown 52 10 2 27 41 (24%) 132 (12%) 
Total 357 (34%) 118 (11%) 194 (18%) 218 (21%) 174 (16%) 1061 
 





Adjudicated First Cardiovascular Composite Events (Secondary Endpoint)* 
Myocardial infarction 173 (25%) 
Stroke 127 (18%) 
Unstable Angina 83 (12%) 
Transient ischaemic attack 34 (5%) 
Procedural Death 2 (<1%) 
Sudden Death 240 (35%) 
Other cardiovascular Death 29 (4%) 
Total 688 
*SUMMIT secondary endpoint was time to first on-treatment cardiovascular composite event (which 
includes on-treatment cardiovascular death). Patients may have experienced multiple cardiovascular 
events, but only the first was used in the analysis 
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Supplementary Appendix A 
 
Principles of Operation of the SUMMIT Clinical Endpoint Committee (CEC) Version 
003  
This document should be used in conjunction with the Charter developed for the SUMMIT CEC 
(HZC113782) protocol and will be updated at subsequent meetings.  
 
Version 001 dated 15Apr2012 
Version 002 dated 02Aug2012 
Version 003 dated 29Jun2014 
 
Assignment of cause of death 
 
The Clinical Endpoint Committee will designate cause of death by probable cause. Causes of death 
will be grouped by general categories, e.g. pulmonary, cardiovascular, cancer, or other. If a cause of 
death cannot be ascertained, the cause of death will be classified as unknown. The general principles 
and methods used in this classification are listed:  
 
Source documentation will be obtained to help in the assignment of cause of death see Appendix 1 
and the form issued in Appendix 4. 
 
The eCRF electronic case report form within the electronic Virtual Clinical Adjudication System 
(VCAS; PAREXEL Inc, Waltham, MA) VCAS system is shown in Appendix 2. 
 
If medical records are inadequate and cannot be obtained as affirmatively stated in the 
documentation, a cause of death will be adjudicated based on the best available evidence of record. 
When information is incomplete, the adjudication of cause of death may rely on information derived 
from the participant’s relatives or the site physician. The use of this information will inform 
assignment of cause of death based on consistency of the information as well as the specificity of 
the information. For example, the attribution of death from a particular type of cancer may be quite 
specific for the purposes of this study. However, terms such as ‘heart attack’ may be considered 
inconclusive with respect to this study in which cardiovascular adverse events are a major outcome.  
 
Medical diagnoses will be based on the principle of Reasonable Degree of Medical Certainty, which 
can be defined as follows: 
 
• The diagnosis is more likely than not 
• The diagnosis is based on the same degree of certainty that would be used in the daily 
practice of medicine 
• A majority of experts in the field would agree with the diagnosis. 
 
The primary cause of death should be attributed to the disorder that causes the patient to present 
for medical treatment. This should be distinguished from terminal events that are the immediate 
cause of death.   
 
• For example, if a patient is admitted to the hospital with a COPD exacerbation, from 
which they do not fully recover, and the patient subsequently develops complications 
such as pneumonia, respiratory failure, renal failure, sepsis or myocardial infarction, the 
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primary cause of death will be attributed to COPD. The myocardial infarction will be 
classified as a cardiovascular event (e.g. myocardial infarction, type 2). 
 
• For example, if a patient undergoes surgery for cancer and dies from complications of 
the surgery or during the immediate postoperative period, the primary cause of death 
will be attributed to cancer, even if the cancer was potentially curable by the surgery. 
 
• For example in general, if a patient is admitted to the hospital with pneumonia and 
develops complications such as respiratory failure, gastrointestinal bleeding, etc. the 
cause of death will be attributed to pneumonia. If it is unclear if a patient is admitted 
with a COPD exacerbation or pneumonia, the cause of death will be based on the 
hospital admission chest radiograph. If pneumonia is present on the admitting chest 
radiograph, the cause of death will be designated pneumonia. If pneumonia is present 
only on subsequent chest radiographs, the cause of death will be designated as COPD. 
 






Sudden death is a term generally denoting a presumed arrhythmic death when the death is 
witnessed and another cause cannot be identified. However, it is more likely that the cause is 
cardiac in nature if the death (not necessarily witnessed) occurred within a reasonable time frame 
(i.e. <1 hour) of the patient last being seen alive and without evidence of clinical deterioration. If the 
interval between death and last being observed alive is between 1 and 24 hours and there is no 
observation of a significantly deteriorating medical condition, then the death is less certain to be of 
cardiac origin and will be classified as unwitnessed sudden death. If the last observation of the 
deceased is >24 hours, and there is no other known cause of death, there is less certainty that the 
cause of death is cardiovascular and will be classified as unknown.   
 
Sub-categories of sudden death are as follows: 
 
 Witnessed (observed in usual health within 1 hour of death event) 
 Unwitnessed (observed in usual health between 1–24 hours of death event) 
 
In cases of out of hospital death, the site coordinator or site physician should interview family or 
witnesses to ascertain the following information: see Appendix 5 for the actual form. 
 
• When was the person last known to be alive? 
• When was the person found to be deceased? 
• What were the events surrounding the death? 
• Did the deceased have any symptoms or change in health status that preceded the 
death? Special reference should be made to shortness of breath, fever, infection, chest 
pain, abdominal pain, fainting, seizures, paralysis and change in mental status. 
• Were there recent medical visits or recent changes in medication? 








In general, the diagnosis of myocardial infarction will require pathologic evidence, or evidence of 
medical record including electrocardiographic tracings, blood enzyme measurements, and 
compatible clinical findings. 
 
 
In circumstances where the source documents such as electrocardiogram tracings or enzyme levels 
are not available, the committee may base a diagnosis of myocardial infarction on other reliable 
medical sources, but should not ordinarily accept death certificate or witness statements for this 




In general, the diagnosis will require compatible clinical findings. With respect to diagnosis of 
stroke: Although brain imaging is ordinarily required for the diagnosis of stroke, if the clinical 
syndrome is compelling (e.g. hemiparesis and aphasia) and follows a typical clinical course for stroke, 
this may be adequate to adjudicate the case as a stroke. Classification of the type of stroke will 
usually require either supportive imaging or pathological evidence. In some cases, a haemorrhagic 
stroke may be supported by a compatible clinical syndrome associated with supportive 
cerebrospinal fluid examination.   
 
Definition of stroke types: 
 
a) ISCHAEMIC: Infarction of brain tissue as a result of either occlusion of a brain artery by 
any mechanism (e.g. thrombosis, embolism), or decreased perfusion selectively 
affecting specific brain arterial territories (e.g. borderzone infarction). 
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b) HAEMORRHAGIC: Damage directly resulting from sudden extravasation of blood into 
the brain tissue (i.e. intracerebral) or the spaces surrounding the brain (e.g. 
subarachnoid). 
c) INDETERMINATE: Information is insufficient to classify. 
 
When a stroke leads to a chronic disabling condition that results in death, the cause of death will be 




A subject with CV cardiovascular disease is taken into hospital for an operation related to 
cardiovascular disease (e.g. percutaneous coronary intervention (PCI), coronary artery bypass graft 




COPD without pneumonia 
 
For the purpose of adjudication, an episode of pneumonia that occurs >5 days after onset of the 
terminal illness will be adjudicated as COPD without pneumonia. The intent is to exclude episodes of 
pneumonia that are secondary complications of a COPD exacerbation, such as ventilator- or 
healthcare-associated pneumonias.   
 
COPD with pneumonia 
 
For the purpose of this study, pneumonia is generally defined as a clinical syndrome compatible with 
pneumonia supported by radiographic evidence. It would be uncommon for a person with COPD to 
have pneumonia without symptoms compatible with a COPD exacerbation; however, it is 
conceivable that such an event might occur. In that case, the death will be coded as ‘Pulmonary – 




For the purpose of adjudication, this diagnosis should be supported by a compatible clinical 
syndrome supported by imaging or pathological evidence. In the absence of definitive imaging or 
pathological evidence, this diagnosis should be supported by a high clinical likelihood supported by 
laboratory and clinical evidence (e.g. evidence of venous thrombosis) as well as a clinical diagnosis of 
the treating physicians. 
 
Other respiratory deaths  
 
If the death is not related to any of the other respiratory categories although is pulmonary in nature 
it will be classified as other respiratory death, e.g. pneumothorax, acute upper airway obstruction, 
pulmonary haemorrhage, or pneumonia in the absence of a COPD exacerbation that are not 




All diagnoses of cancer should generally be corroborated by the primary medical record. This should 
include imaging studies, histologic diagnoses, operative or procedure notes, and records of 
treatment. If the primary medical record cannot be obtained to confirm the diagnosis, this should be 
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affirmatively stated in the documentation, and the committee will determine a diagnosis based on 
their best judgment. Haematological malignancies will be classified as cancer for the purpose of 
adjudication.   
 
Patients who die with an uncured cancer that would be expected to be fatal will be designated as 
dying from the cancer. Exceptions to this may include cancers that if left untreated would not be 
expected to lead to death within 5 years. Examples of such cancers include non-melanoma skin 
cancers, localised prostate cancer or low-grade haematological malignancies.   
 
For example, a patient with documented gastric cancer who dies of gastrointestinal haemorrhage 
will be classified to have died from gastric cancer. A patient who dies from neutropenic sepsis while 
undergoing chemotherapy for lymphoma will be classified as dying from lymphoma. 
 
Sub-categorisation of cancer death will be lung, breast, colorectal or other. Other cancers will be 
submitted as free text. 
 
Death other specify 
 
If a subject commits suicide (e.g. by shooting themselves in the head, taking an overdose of pills, 
jumping off a bridge and drowning) the cause of death will be designated as ‘Other – suicide’, not 
‘Other (mode of suicide)’.  
 
If a subject has an accident and causes injury to their head that causes death, it should be classified 




In some circumstances, the cause of death cannot be determined based on the evidence available to 
the committee. This includes deceased who are found deceased after >24 hours have elapsed since 
they were last observed in their usual state of health and where no other cause of death is apparent. 
The cause of death may be unknown either, because the medical information is adequate but the 
cause of death is ‘indeterminate’. Such cases should be sub-categorised as indeterminate. In some 
cases, medical information may exist, but is not available for review. In those cases, the case should 
be sub-categorised as ‘inadequate information’. 
 
Procedure for dealing with multiple SAEs serious adverse events for a single death 
 
If a subject has multiple fatal serious adverse eventsSAEs, these will be combined into one death 
episode in virtual clinical adjudication system VCAS and adjudicated as one death event.  
 
 
2. Determination of COPD relatedness 
All cases will have a secondary classification to determine whether the death is related to COPD. The 
possible choices are NO/UNLIKELY, YES/PROBABLE, UNKNOWN. 
 
1. All cases where primary cause of death is COPD will be classified as YES. 
 
2. In cases where primary cause of death is NOT COPD the classification of COPD 




• If the terminal event is documented to be hypercapnic respiratory failure or 
failure to wean from a ventilator the case will be classified YES. 
– For example, patient dies in hospital on ventilator, but succumbs to fatal 
pneumonia, arrhythmia, or care is withdrawn.  
• If the patient would have been judged to have survived the terminal illness had 
COPD not been present, the case will be classified YES 
– For example, patient dies from Stage I lung cancer because they have 
insufficient lung function to undergo surgery. 
– For example, patient has pneumonia or influenza that is fatal. 
• If the death occurs at home, where the patient is receiving palliative care for 
advanced COPD, the case will be classified YES. 
– For example, a patient receiving continuous oxygen, confined to bed and 
chair, with cor pulmonale, or with advanced malnutrition.   
• If the terminal event is NOT respiratory, and would be likely fatal for patients 
without COPD, the case will be classified NO. 
– For example, death from metastatic cancer, cerebral haemorrhage, severe 
cardiomyopathy or cardiogenic shock. 
• If there is another clear explanation for terminal respiratory failure that would 
likely have occurred in patients without COPD, then the case will be classified NO. 
– For example respiratory failure secondary to CVcardiovasculara, drug 
overdose or asphyxia.   
 
3. If the data are inadequate to make a clear YES/PROBABLE or NO/UNLIKELY 
classification, it will be designated as UNKNOWN, based on the best evidence available. 
UNKNOWN will be classified as either, indeterminate or inadequate information. 
 
Cardiovascular events  
 
For the purpose of this study, the cardiovascular endpoint comprises MImyocardial infarction, 
stroke, TIAtransient ischaemic attack, unstable angina and on-treatment cardiovascular death. The 
cardiovascular electronic case report formCRF page is shown in Appendix 3. The committee will 
require supportive evidence from the medical records in order to classify an adverse event as a 
cardiovascular event for this study.   
 
Non-serious possible cardiovascular adverse event only: Investigator declaration, Appendix 6 
 
Non-serious cardiovascular adverse events occasionally are being reported with no source 
documentation available. This is usually caused by subject self-reporting/diary entry at scheduled 
study visit, thus there is no evidence for protocol-defined event. 
 
The non-serious possible cardiovascular adverse event only: Investigator Declaration, Appendix 6, 
was developed to find out if the site investigator believed the reported event could be a study 
endpoint (unstable angina, myocardial infarction, transient ischaemic attack or stroke) by answering 
yes or no to question #1. If yes, further documentation is requested of the site. If no, the site 




In cases where a Non-Serious AEadverse event  of chest pain or a similar term triggers an 
event and the clinical study site is unable to obtain medical evidence, the site investigator 
8 
 
will be asked to answer question #2 within ‘The non-serious possible cardiovascular adverse 
event only: Investigator declaration’ to assess cardiac cause.  
 
If the site investigator declares that the event is ‘non-cardiac’ chest pain, and there is no 
medical evidence to review, then the event will be administratively determined (deleted in 
virtual clinical adjudication systemVCAS) not to be a protocol defined endpoint and will not 
go to the committee for further review. If there is medical evidence of record for the 
committee to review such as clinical notes, SAE serious adverse event reports, laboratory 
findings, or ECGselectrocardiographs, then the event will be reviewed by the committee 
regardless of the investigator’s declaration. 
 
Triage process for AEs adverse events  
 
It was agreed by the CEC and GSK GlaxoSmithKline plc. to create a triage process for AEs adverse 
events only (note: all SAEs serious adverse events automatically go to the independent round). This 
triage process in virtual clinical adjudication VCAS  would initially be completed by one CEC member 
only. The eCRF electronic case report form in VCAS asks ‘This is an event which needs further 
adjudication as it may be TIAtransient ischaemic attack, stroke, UAunstable angina or myocardial 
infarctionMI’ [Yes/No], If ‘Yes’ it would go to the ‘independent’ round for full committee review or if 




Generally, the definition provided by Thygesen 2007 will be used to determine myocardial infarction. 
 
‘The diagnosis of myocardial infarction will require pathologic evidence, or evidence of medical 
record including electrocardiographic tracings, blood enzyme measurements, and compatible clinical 
findings’. 
 
Myocardial infarctions will be sub-classified as follows: 
 
• Type 1 – Spontaneous myocardial infarction related to ischaemia due to a primary event 
such as plaque erosion or rupture fissuring or dissection. 
• Type 2 – Myocardial infarction secondary to ischaemia due to imbalance between 
oxygen demand and supply, e.g. coronary spasm, anaemia or hypotension. This type of 
event would typically occur in the context of another illness that may or may not be 
fatal. 
• Procedure related – Myocardial infarction associated with percutaneous coronary 
intervention PCI or in association with a coronary artery bypass graftCABG. This 
category includes both type 4 and type 5 myocardial infarction according to the 
Universal definitions.   
 
(Type 3 myocardial infarctions are associated with sudden death and will be coded as a death event 




Symptoms of myocardial ischaemia at rest (chest pain or equivalent) or an accelerating pattern of 
angina with frequent episodes associated with progressively decreased exercise capacity that 
prompts an unscheduled visit to a healthcare facility. One of the following should also be observed 




1) New or worsening ST or T-wave changes on resting ECG electrocardiograph  
a. ST elevation  
 
New ST elevation at the J point in two anatomically contiguous leads with the 
cut-off points: ≥0.2 mV in men (>0.25 mV in men <40 years) or ≥0.15 mV in 
women in leads V2–V3 and/or ≥0.1 mV in other leads.  
 
b. ST depression and T-wave changes  
New horizontal or down-sloping ST depression ≥ 0.05 mV in two contiguous 
leads; and/or new T inversion ≥0.1 mV in two contiguous leads.  
 
It is recognised that lesser ECG echocardiograph abnormalities may represent 
an ischaemic response and may be accepted under the category of abnormal 
ECG echocardiograph findings.  
 
2) Definite evidence of myocardial ischaemia on myocardial scintigraphy (clear reversible 
perfusion defect), stress echocardiography (reversible wall motion abnormality), or MRI 
(myocardial perfusion deficit under pharmacologic stress) that is believed to be 
responsible for the myocardial ischaemic symptoms/signs  
 
3) Angiographic evidence of ≥70% lesion and/or thrombus in an epicardial coronary artery 
that is believed to be responsible for the myocardial ischaemic symptoms/signs. 
 
4) Need for coronary revascularisation procedure (percutaneous coronary intervention PCI 




In general, the diagnosis will require compatible clinical findings. Classification of the type of stroke 
will usually require either supportive imaging or pathological evidence. In some cases, a 
haemorrhagic stroke may be supported by a compatible clinical syndrome associated with 
supportive cerebrospinal fluid examination.   
 
Definition of stroke types: 
 
a) ISCHAEMIC: Infarction of brain tissue as a result of either occlusion of a brain artery by 
any mechanism (e.g. thrombosis, embolism), or decreased perfusion selectively 
affecting specific brain arterial territories (e.g. borderzone infarction). 
b) HAEMORRHAGIC: Damage directly resulting from sudden extravasation of blood into 
the brain tissue (i.e. intracerebral) or the spaces surrounding the brain (e.g. 
subarachnoid). 
c) INDETERMINATE: Information is insufficient to classify, but the clinical course is 
suggestive of a stroke. 
 
Transient ischaemic attack 
 
Temporary focal neurologic deficit is defined as either witnessed by a physician or recorded by a 
physician as a credible and objectively witnessed event, AND presumably resulting from brain 
ischaemia, AND lasting less than 24 hours, AND without any evidence of appropriate ischaemic 
Commented [JL1]: Authors, acronyms have been removed 
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changes in either CT computed tomography or MRI magnetic resonance imaging if either of these 
obtained. 
 
None of the above 
 
The event does not meet the definition of an adverse cardiovascular event as listed above.   
 
Related to previous CV cardiovascular event 
 
If based on the information in the endpoint adjudication package, the CEC determines this is related 
to a previously adjudicated event then it will be marked as such and not counted as a new event. 
The previous AEadverse event reference ID identifier will be added to the eCRF electronic case 
report form by the CEC.   
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Appendix 1  
 
Documents provided to the Clinical Endpoint Committee (CEC) for adjudication 
 
Whenever possible, potential endpoints will be sent to the CEC only when all appropriate case 
report forms (CRFs) and a completed dossier of the information have been obtained. Also, if multiple 
related or evolving events occur in a single subject, whenever possible, the set of the events will be 
kept together and sent to the CEC only when all documents for all events are complete. These may 
include but are not limited to:  
 
• Death certificate  
• Discharge summary 
• Imaging and procedure notes 
• Surgical operation reports 
• Hospital records and outpatient records 
• Physician notes (i.e. from office or clinic) 
• Witness accounts, including non-hospital death where narratives from friends and relatives. 
A proforma will be developed with questions  
• Autopsy reports 
• Pathology reports 
• Serious AEadverse event reports 
• ECG Echocardiograph reports 
• Pertinent radiologic reports (i.e. plain films/MRImagnetic resonance imaging/CTcomputed 
tomography) 
• CRF Case report form reports, including con-meds, past history, demography 
• Labs including troponins and cardiac enzymes 
• Coronary angiogram reports (with no intervention) 
• Carotid ultrasound reports 
• Angiogram of head and neck procedures coronary artery bypass graftCABG, and 
percutaneous coronary interventions PCIs reports 








Abbreviations: CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; 
CV, cardiovascular; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart 
Failure; PCI, percutaneous coronary intervention.  
  
       indeterminate    
  
2   Was the death  
COPD related   
       No or unlikely   
          
       Yes or probable   
  
       Unknown   
           inadequate information   
           indeterminate   
  
  




* defined as per MERIT - HF trial , Lancet 1999   
  
  
Tier   Questions   Responses   
1   Classify the  
primary cause of  
death   
  Cardiovascular   
        Sudden Death*   
               Witnessed   less than 1 hour   
               Un w itnessed  1 – 24 hours      
        Myocardial Infarction   
        Stroke   
               Hemorrhagic   
               Ischemic     
                Indeterminate   
  
        Procedural death   (related to PCI, CABG or during  
insertion of other cardiac device)    
        Other, specify   
  
_____________________________________   
  Pulmonary   
        COPD    
            with pneumonia   
              without pneumonia   
     
        Pulmonary embolism   
        Other, specify      
______________________________________     
  Cancer   
        Lung   
        Breast   
        Colorectal   
        Other, specify   
______________________________________   
  Other, specify    
  
   Unknown, specify   (includes sudden death >24hrs )   





Abbreviation: CV, cardiovascular  
Tier   Questions   Responses   
1   Is this event a      Myocardial Infarction   
        Type 1   
        Type 2   
        Procedural related   
  
  Unstable Angina   
  Stroke   
          Hemorrhagic   
        Ischemic   
        Indeterminate   
        
  Transient Ischemic Attack   
  
  None of the above   
A.     No evidence for protocol defined CV  
event   
B.     Related to  previous  CV  event   
             Adverse  Event  
ID____________________   






(R emark on  
adjudication  
















CEC Collection Form  
Date  
Centre Number  Subject Number  
Clinical Event Term  
(AE term as entered in DataLabs)  
 
Event Onset Date  
Please provide the following source documents and make sure the centre/subject study numbers 
are marked on each document. Remove all patient identifiers. Check one box per line item and 
provide this form with the source returned: 











1 Death certificate      
2 Discharge summary      
3 Imaging and procedure notes      
4 Surgical operation reports      
5 Hospital records and outpatient 
records 
     
6 Physician notes (from office or clinic)      
7 
**Non-hospital death witness account 
with details from friends and relatives 
(non-hospital death questionnaire, 
Appendix 5) 
     
8 Autopsy reports      
9 Pathology reports      
10 SAE reports (if not already submitted)      
11 ECG reports      
12 Pertinent radiologic reports      
13 
CRF reports (please make sure con-
meds, past history, demography are 
updated in DataLabs) 
     
14 Labs including troponins and cardiac 
enzymes 
     
15 Coronary angiogram reports (with no 
intervention) 
     
16 Carotid ultrasound reports      
17 Angiogram of head and neck 
procedures, CABG, PCI reports 
     






Investigator’s Signature: ...............................  Date: ............................. 
 
• Please return the completed table, including the Investigator’s signature, with all 
available source documents to PAREXEL  
• To assist with the CEC review, kindly respond within 2 weeks. 
 
 
Abbreviations: AE, adverse event; CABG, coronary artery bypass graft; CEC, Clinical Endpoint 
Committee; COPD, chronic obstructive pulmonary disease; CRF, case report form; ECG, 





GSK Protocol HZC113782 SUMMIT – 
 
Non-hospital death witness questionnaire 
 
Date  
Centre Number  Subject Number  
Event Onset Date  
 
**In cases of out of hospital death, the site coordinator or site physician should interview family or 
witnesses to ascertain the following information: 
 
Investigator’s Signature: .........................................   Date: .............................. 
• If applicable, please return the completed questionnaire, including the 
Investigator’s signature, with CEC Collection Form and associated documents to 
PAREXEL  
• To assist with the CEC review, kindly respond within 2 weeks. 
 
Abbreviation: CEC, Clinical Endpoint Committee.  
1 When was the person last known to be 
alive? 
 
2 When was the person found to be 
deceased? 
 




Did the deceased have any symptoms 
or change in health status before the 
death? Special attention should be 
made to shortness of breath, fever, 
infection, chest pain, abdominal pain, 
fainting, seizures, paralysis and change 
in mental status. 
 
5 Were there recent medical visits or 
recent changes in medication? 
 





GSK Protocol HZC113782 SUMMIT 
 




Centre Number  Subject Number  
Clinical Event Term  
(AE term as entered in DataLabs)  
 
Event Onset Date  
 
If no source documents are available due to subject self-reporting for CV events, site 
investigator will need to complete this form: 
 
**Please complete for chest pain or similar term regardless of your assessment of cause.  
 
1. Is this event part of a study endpoint (myocardial infarction, unstable angina, transient ischaemic 
attack or stroke)?        
□ YES □NO 
 
If YES, please provide additional evidence (documentation) to support this assessment. 
If NO, please sign and date this form and return per instructions below. 
 
2. If this event is CHEST PAIN or a similar term, then complete the following: 
 
Please tick to indicate which one of the following applies: 
___ This event is likely cardiac or ischaemic chest pain 
____This event is NOT likely cardiac or ischaemic in origin 
___ It is indeterminate whether this event is cardiac or ischaemic in origin 
 
Investigator comments:  
 
________________________________________________  ___________________ 
Investigator’s Signature       Date 
• If applicable, please return the completed questionnaire, including the 
Investigator’s signature, with CEC Collection Form and associated documents to 
PAREXEL via fax: +1 781 434 5957 or email: GSKSUMMITCEC@PAREXEL.com  
• To assist with the CEC review, kindly respond within 2 weeks. 
 
 
Abbreviations: AE, adverse event; CEC, Clinical Endpoint Committee; CV, cardiovascular. Formatted: Font: 11 pt, Not Bold
Formatted: Font: 11 pt, Not Bold
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Supplementary Appendix B 
Figure S1. 
Number of cardiovascular events triggered by MedDRAMedical Dictionary for Regulatory Activities 





Table S1.  
Triggered MedDRAMedical Dictionary for Regulatory Activities preferred terms that resulted in no 
CVcardiovascular events. 
 
Preferred term Number triggered 
Number of CV 
cardiovascular 
events 
Cardiac failure 160 0 
Syncope 92 0 
Peripheral arterial occlusive disease 91 0 
Palpitations 74 0 
Aortic aneurysm 54 0 
Cardiac failure chronic 50 0 
Hypoesthesia 50 0 
Ventricular extrasystoles 34 0 
Peripheral artery stenosis 24 0 
Arteriosclerosis 21 0 
Cor pulmonale 21 0 
Presyncope 21 0 
Cardiac failure acute 20 0 
Peripheral ischaemia 20 0 
Pulmonary congestion 20 0 
Intermittent claudication 19 0 
Peripheral venous disease 19 0 
Pulmonary oedema 19 0 
Vascular encephalopathy 18 0 
Sudden cardiac death 17 0 
Loss of consciousness 16 0 
Ventricular tachycardia 16 0 
Congestive cardiomyopathy 15 0 
Ischaemic cardiomyopathy 14 0 
Left ventricular failure 14 0 
Cardiopulmonary failure 13 0 
Femoral artery occlusion 13 0 
Somnolence 13 0 
Iliac artery occlusion 12 0 
Carotid arteriosclerosis 10 0 
Circulatory collapse 9 0 
Confusional state 9 0 
Left ventricular dysfunction 9 0 
Left ventricular hypertrophy 9 0 
Carotid artery occlusion 8 0 
Cerebral arteriosclerosis 8 0 
Lethargy 8 0 
Pain in jaw 8 0 
Seizure 8 0 
Aortic aneurysm rupture 7 0 
Ventricular fibrillation 7 0 
Vertebrobasilar insufficiency 7 0 
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Preferred term Number triggered 
Number of CV 
cardiovascular 
events 
Cerebral ischaemia 6 0 
Diabetic microangiopathy 6 0 
Diastolic dysfunction 6 0 
Aphonia 5 0 
Cardiovascular disorder 5 0 
Cerebrovascular insufficiency 5 0 
Epilepsy 5 0 
Accelerated hypertension 4 0 
Arterial occlusive disease 4 0 
Blindness 4 0 
Bradyarrhythmia 4 0 
Brain oedema 4 0 
Cardiogenic shock 4 0 
Raynaud's phenomenon 4 0 
Subclavian artery stenosis 4 0 
Tachyarrhythmia 4 0 
Aneurysm 3 0 
Aortic dissection 3 0 
Aphasia 3 0 
Arterial stenosis 3 0 
Cardiac fibrillation 3 0 
Cardiomegaly 3 0 
Cardiovascular insufficiency 3 0 
Cerebral microangiopathy 3 0 
Cyanosis 3 0 
Dilatation atrial 3 0 
Hypovolemic shock 3 0 
Intracranial aneurysm 3 0 
Right ventricular failure 3 0 
Vascular graft occlusion 3 0 
Venous occlusion 3 0 
Ventricular arrhythmia 3 0 
Ventricular hypokinesia 3 0 
Arterial stent insertion 2 0 
Atrial thrombosis 2 0 
Cardiac discomfort 2 0 
Carotid artery aneurysm 2 0 
Carotid bruit 2 0 
Catheterisation cardiac 2 0 
Coma 2 0 
Convulsions local 2 0 
Coronary artery thrombosis 2 0 
Coronary ostial stenosis 2 0 
Diabetic vascular disorder 2 0 
Dysarthria 2 0 
Ejection fraction decreased 2 0 
Hemiparesis 2 0 
Hyporeflexia 2 0 
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Preferred term Number triggered 
Number of CV 
cardiovascular 
events 
Intraventricular haemorrhage 2 0 
Orthopnoea 2 0 
Peripheral coldness 2 0 
Poor peripheral circulation 2 0 
Sensory loss 2 0 
Speech disorder 2 0 
Troponin increased 2 0 
Vasoconstriction 2 0 
Amaurosis 1 0 
Apraxia 1 0 
Arterial bruit 1 0 
Arteriogram coronary 1 0 
Basilar artery occlusion 1 0 
Basilar artery thrombosis 1 0 
Blindness unilateral 1 0 
Brain natriuretic peptide increased 1 0 
Brain stem stroke 1 0 
Cardiac aneurysm 1 0 
Cardiac death 1 0 
Cardiac disorder 1 0 
Cardiac function disturbance postoperative 1 0 
Cardiac pacemaker evaluation 1 0 
Cardiac pacemaker insertion 1 0 
Cardiac ventricular thrombosis 1 0 
Cardio-respiratory distress 1 0 
Cerebral artery stenosis 1 0 
Cerebral artery thrombosis 1 0 
Complex partial seizures 1 0 
Cor pulmonale acute 1 0 
Cor pulmonale chronic 1 0 
Coronary artery insufficiency 1 0 
Coronary vascular graft occlusion 1 0 
Diplegia 1 0 
Disorientation 1 0 
Dry gangrene 1 0 
Extremity necrosis 1 0 
Eye disorder 1 0 
Generalised tonic-clonic seizure 1 0 
Haemorrhage intracranial 1 0 
Haemorrhagic cerebral infarction 1 0 
Hypertensive cardiomyopathy 1 0 
Intracranial pressure increased 1 0 
Ischaemia 1 0 
Motor dysfunction 1 0 
Myocardial fibrosis 1 0 
Neuritis cranial 1 0 
Night blindness 1 0 
Paresis 1 0 
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Preferred term Number triggered 
Number of CV 
cardiovascular 
events 
Penetrating atherosclerotic ulcer 1 0 
Pericarditis 1 0 
Peripheral circulatory failure 1 0 
Postictal paralysis 1 0 
Pseudoangina 1 0 
Pulseless electrical activity 1 0 
Right atrial dilatation 1 0 
Right atrial hypertrophy 1 0 
Ruptured cerebral aneurysm 1 0 
Seizure like phenomena 1 0 
Shock haemorrhagic 1 0 
Troponin I increased 1 0 
Ultrasound Doppler abnormal 1 0 
Vascular graft thrombosis 1 0 
Vascular occlusion 1 0 
Vascular pseudoaneurysm 1 0 
Vascular stenosis 1 0 
Ventricle rupture 1 0 
Ventricular failure 1 0 
Ventricular hypertrophy 1 0 





Table S2.  
Agreement of individual adjudicators on round 1 with final committee adjudication of primary 
classification of death (cardiovascularcardiovascular, pulmonary, cancer, other cause or unknown). 
 
 # cases reviewed 
# agree with final 
adjudication Percent agreement (%) 
Adjudicator 1 800 648 81 
Adjudicator 2 710 644 91 
Adjudicator 3 653 551 84 
Adjudicator 4 248 185 75 
Adjudicator 5 753 652 87 
Adjudicator 6 714 606 85 
Total* 3,878 3,286 85 
 
* There were more cases (3,878) than adverse events (3,314) because some adverse events were 
reviewed by more than one adjudicator in round 1. 
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On or post-treatment deaths, including 
post common end date for participants






Myocardial infarction  
Stroke
Sudden death
PR death  
Other cardiovascular
Cancer
Lung
Breast
Colorectal
Other
Other
Unknown
TOTAL
138 (13%)
126 (12%)
3 (<1%)
9 (1%)
459 (43%)
42 (4%)
42 (4%)
320 (30%)
6 (1%)
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3 (<1%)
12 (1%)
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